Valuation: Alector, Inc.

Market Cap 182M 159M 146M 135M 257M 17.33B 261M 1.75B 687M 8.51B 681M 667M 29.47B P/E 2026 *
-1.91x
P/E 2027 * -2.55x
Enterprise Value -65.61M -57.39M -52.93M -48.97M -92.95M -6.26B -94.5M -634M -248M -3.08B -246M -241M -10.65B EV / Sales 2026 *
-9.57x
EV / Sales 2027 * -6.33x
Free-Float
86.83%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-10.66%
1 week-20.63%
Current month-18.66%
1 month+0.31%
3 months-31.88%
6 months-12.10%
Current year+4.81%
1 week 1.6
Extreme 1.6
2.06
1 month 1.41
Extreme 1.41
2.14
Current year 1.41
Extreme 1.41
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
39.22
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 30/04/2013
Director of Finance/CFO 52 19/06/2025
Chief Tech/Sci/R&D Officer - 31/12/2016
Director TitleAgeSince
Director/Board Member 72 18/03/2024
Chairman 77 12/06/2023
Director/Board Member 72 30/09/2018
Date Insider Type Main position Quantity % Market Cap.
06-16Free

Director

38,150 0.0344%
06-16Free

Director

38,150 0.0344%
06-16Free

Chairman

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
-10.66%-20.63%-0.91%-73.46% 182M
-0.13%-4.21%+63.95%+126.34% 56.98B
+4.91%-0.19%+73.70%+92.14% 53.58B
+1.48%+5.97%+22.59%+495.47% 25.63B
-0.59%-4.68%-16.82%-12.99% 23.51B
+2.43%+1.01%+47.63%-0.16% 19.43B
-0.39%+2.97%+37.97%-24.70% 18.12B
-6.84%+2.18%+203.03%+348.11% 16.46B
+8.00%+2.71%+52.62% - 14.13B
+1.76%+2.24%+29.57%+195.70% 14.35B
Average -0.04%-1.29%+51.33%+127.38% 24.24B
Weighted average by Cap. +1.40%-0.33%+57.34%+142.84%

Financials

2026 *2027 *
Net sales 6.86M 6M 5.53M 5.12M 9.71M 655M 9.88M 66.24M 25.97M 321M 25.74M 25.18M 1.11B 22.88M 20.02M 18.46M 17.08M 32.42M 2.18B 32.96M 221M 86.65M 1.07B 85.9M 84.04M 3.72B
Net income -94.11M -82.33M -75.92M -70.24M -133M -8.98B -136M -909M -356M -4.41B -353M -346M -15.28B -96.62M -84.52M -77.94M -72.11M -137M -9.22B -139M -933M -366M -4.53B -363M -355M -15.69B
Net Debt -247M -216M -199M -184M -350M -23.59B -356M -2.39B -936M -11.58B -928M -908M -40.13B -326M -286M -263M -244M -462M -31.15B -470M -3.15B -1.24B -15.3B -1.23B -1.2B -52.99B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
09/07/26 US$1.635 -10.66% 589,285
08/07/26 US$1.830 -5.18% 643,891
07/07/26 US$1.930 -0.52% 416,164
06/07/26 US$1.940 -5.83% 588,496
02/07/26 US$2.060 +2.49% 394,059
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.635USD
Average target price
3.100USD
Spread / Average Target
+89.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock